1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,523 | 0,567 | 14:38 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | Cereno Scientific AB: Cereno Scientific extends patent protection for drug candidate CS1 in the US and has filed to extend market exclusivity to 2045 | 173 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 12.03. | Cereno Scientific secures FDA meeting to advance its development of CS1 for the treatment of rare disease PAH | 3 | Cision News | ||
| 28.02. | Cereno Scientific shares invitation to the webcast for the CS1 Phase IIa trial data presentation at 14:00 CET on March 4 | 1 | Cision News | ||
| 26.02. | CERENO SCIENTIFIC: Additional data strengthens Cereno's CS1 in PAH | 1 | Cision News | ||
| 25.02. | Cereno Scientific AB: Cereno Scientific publishes Year-end Report for 2024 (January 1 - December 31, 2024) | 80 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 25.02. | Cereno Scientific's lead candidate CS1's reverse vascular remodeling profile is accompanied by improvement of right-ventricular function in additional data from Phase IIa trial - webcast on March 4 | 1 | Cision News | ||
| 20.02. | Cereno Scientific to evaluate CS1 with advanced imaging technology | 1 | Cision News | ||
| 20.02. | Cereno Scientific submitted Type C meeting request with FDA for Phase II drug candidate CS1 in preparation for further clinical development | 1 | Cision News | ||
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 19.02. | Cereno Scientific received approval to initiate sub-study of the CS1 EAP using Fluidda's innovative imaging technology to obtain insights on the long-term disease-modifying potential of CS1 in PAH | 2 | Cision News | ||
| 14.02. | Cereno Scientific to attend BIO-Europe Spring 2025 - a leading partnering event for life science in Europe | 3 | Cision News | ||
| 13.02. | Cereno Scientific - CS014 achieves another Phase I milestone | 188 | Edison Investment Research | Cereno Scientific's second pipeline asset, CS014, continues to make steady progress through the clinic, with the company successfully completing the single ascending dose (SAD) part of the Phase I study... ► Artikel lesen | |
| 11.02. | Cereno Scientific's HDAC inhibitor CS014 advances | 1 | Cision News | ||
| 11.02. | Cereno Scientific's HDACi CS014 has successfully completed part one of its Phase I trial evaluating the safety profile with a single ascending dose (SAD) study | 1 | Cision News | ||
| 06.02. | Cereno Scientific to present at the 2025 Nordic-American Healthcare Conference, the most comprehensive Nordic life science innovation gathering in the US | 1 | Cision News | ||
| 27.12.24 | Cereno Scientific has enrolled 9 additional patients in its Expanded Access Program with CS1 providing more long-term safety and efficacy data in rare disease PAH | 2 | Cision News | ||
| 20.12.24 | Cereno Scientific announces that the registration of warrants and convertibles to Fenja and Arena has been completed and that delivery of the warrants has been initiated | 1 | Cision News | ||
| 16.12.24 | New preclinical data for Cereno Scientific's novel IP Receptor Agonist CS585 presented at the ASH Annual Meeting and Exposition 2024 | 1 | Cision News | ||
| 13.12.24 | Cereno Scientific to present and engage in partnering and investor meetings at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco | 3 | Cision News | ||
| 06.12.24 | Cereno Scientific to present preclinical data for drug candidate CS585 at the ASH Annual Meeting and Exposition 2024 | 1 | Cision News | ||
| 29.11.24 | Cereno Scientific reports insider share purchases | 1 | Cision News |
Seite:
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 48,240 | 0,00 % | Why Tempus AI Inc. (TEM) Crashed On Wednesday? | ||
| PRAXIS PRECISION MEDICINES | 37,870 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| DYNE THERAPEUTICS | 10,460 | 0,00 % | Dyne Therapeutics (NASDAQ:DYN) Trading 5.4% Higher - What's Next? | ||
| QIAGEN | 37,365 | +1,88 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
| BEAM THERAPEUTICS | 19,545 | 0,00 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,285 | 0,00 % | Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today | ||
| ADMA BIOLOGICS | 19,820 | 0,00 % | How IBD Stock Of The Day ADMA Biologics Shrugged Off Accounting Debacle For A Bullish Comeback | ||
| SPRINGWORKS THERAPEUTICS | 44,150 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 29,510 | 0,00 % | Avidity Biosciences Inc Aktie: Neue Marktbedingungen, was bedeutet das? | Avidity Biosciences verzeichnete am Freitag einen Kursrückgang von 2,95 Prozent auf 31,60 USD. Trotz dieser kurzfristigen Schwäche konnte das Unternehmen im Monatsvergleich ein Plus von 7,67 Prozent... ► Artikel lesen | |
| EVOTEC | 6,170 | +1,82 % | Evotec, NetraMark, Novo Nordisk - vom Labor zur goldenen digitalen Zukunft mit Künstlicher Intelligenz | Die Pharmabranche erlebt eine Revolution, die alles verändert! Künstliche Intelligenz jagt durch die Labore und schneidet alte Zöpfe ab. Algorithmen durchforsten Milliarden chemischer Strukturen in... ► Artikel lesen | |
| NUVALENT | 70,88 | 0,00 % | Nuvalent-Entwicklungschefin verkauft Aktien im Wert von 292.468 US-Dollar | ||
| BIONTECH | 84,40 | +2,37 % | Biontech-Partner unter Druck: Schwerer Vorwurf an Pfizer: War der Covid-Impfstoff viel früher ready? | © Foto: picture alliance/pressefoto_korb/Micha Korb - pressefoto_korb picture alliance/pressefoto_korb/Micha KorbIm Zentrum steht die Frage: Hat Pfizer die Bekanntgabe des Erfolgs seines gemeinsam mit... ► Artikel lesen | |
| IMMUNOVANT | 17,080 | 0,00 % | Immunovant Inc.: Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
| VERA THERAPEUTICS | 24,020 | 0,00 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
| ARVINAS | 7,010 | 0,00 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen |
CERENO SCIENTIFIC AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,026 (+5,09 %) liegt der Kurs bei 0,526 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.
